id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1167-0014,FDA,FDA-2014-D-1167,"Agency Information Collection Activities; Announcement of Office 
of Management and Budget Approval; Guidance for Industry on Controlled Correspondence Related to Generic Drug Development",Notice,Notice of Approval,2015-10-30T04:00:00Z,2015,10,2015-10-30T04:00:00Z,,2019-06-18T16:45:55Z,2015-27741,0,0,0900006481cfcaa7
FDA-2014-D-1167-0012,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry; Availability,Notice,Notice of Availability,2015-09-29T04:00:00Z,2015,9,2015-09-29T04:00:00Z,,2015-09-29T14:14:27Z,2015-24621,0,0,0900006481ca0e1f
FDA-2014-D-1167-0013,FDA,FDA-2014-D-1167,"Controlled Correspondence Related to Generic Drug Development
Guidance for Industry",Other,Guidance,2015-09-29T04:00:00Z,2015,9,2015-09-29T04:00:00Z,,2019-06-18T16:45:38Z,,0,0,0900006481ca1ef1
FDA-2014-D-1167-0003,FDA,FDA-2014-D-1167,Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Controlled Correspondence Related to Generic Drug Development,Notice,30 Day Proposed Information Collection,2015-07-02T04:00:00Z,2015,7,2015-07-02T04:00:00Z,2015-08-04T03:59:59Z,2015-08-04T01:30:57Z,2015-16358,0,0,0900006481b670a4